1. Home
  2. CGEM vs AVBP Comparison

CGEM vs AVBP Comparison

Compare CGEM & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEM
  • AVBP
  • Stock Information
  • Founded
  • CGEM 2016
  • AVBP 2021
  • Country
  • CGEM United States
  • AVBP United States
  • Employees
  • CGEM N/A
  • AVBP N/A
  • Industry
  • CGEM Biotechnology: Pharmaceutical Preparations
  • AVBP
  • Sector
  • CGEM Health Care
  • AVBP
  • Exchange
  • CGEM Nasdaq
  • AVBP NYSE
  • Market Cap
  • CGEM 1.0B
  • AVBP 948.5M
  • IPO Year
  • CGEM 2021
  • AVBP 2024
  • Fundamental
  • Price
  • CGEM $15.63
  • AVBP $30.78
  • Analyst Decision
  • CGEM Strong Buy
  • AVBP Strong Buy
  • Analyst Count
  • CGEM 7
  • AVBP 5
  • Target Price
  • CGEM $31.67
  • AVBP $36.80
  • AVG Volume (30 Days)
  • CGEM 362.4K
  • AVBP 129.8K
  • Earning Date
  • CGEM 11-15-2024
  • AVBP 11-15-2024
  • Dividend Yield
  • CGEM N/A
  • AVBP N/A
  • EPS Growth
  • CGEM N/A
  • AVBP N/A
  • EPS
  • CGEM N/A
  • AVBP N/A
  • Revenue
  • CGEM N/A
  • AVBP N/A
  • Revenue This Year
  • CGEM N/A
  • AVBP N/A
  • Revenue Next Year
  • CGEM N/A
  • AVBP N/A
  • P/E Ratio
  • CGEM N/A
  • AVBP N/A
  • Revenue Growth
  • CGEM N/A
  • AVBP N/A
  • 52 Week Low
  • CGEM $7.64
  • AVBP $14.35
  • 52 Week High
  • CGEM $30.19
  • AVBP $32.40
  • Technical
  • Relative Strength Index (RSI)
  • CGEM 44.37
  • AVBP 60.13
  • Support Level
  • CGEM $15.55
  • AVBP $30.70
  • Resistance Level
  • CGEM $16.93
  • AVBP $32.40
  • Average True Range (ATR)
  • CGEM 0.80
  • AVBP 1.37
  • MACD
  • CGEM -0.00
  • AVBP -0.04
  • Stochastic Oscillator
  • CGEM 12.57
  • AVBP 67.47

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

About AVBP ARRIVENT BIOPHARMA INC

ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Share on Social Networks: